PharmaBiome AG

PharmaBiome develops a pipeline for the use of beneficial gut bacteria as an innovative, standardized and safe therapeutic product to treat diseases caused by functional deficiencies in the microbiome (i.e. gut flora), with an initial focus on ulcerative colitis (UC). Using its proprietary technology platform including isolation, cultivation and rational assembly of intestinal bacterial mixtures, PharmaBiome develops tailored microbiome products. The flexibility and speed of development are a unique advantage to penetrate the multibillion markets of untreatable intestinal diseases.